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A B S T R A C T
Hemophagocytic lymphohystiocytosis (HLH) represents a severe hyperinflammatory condition with the cardinal sym-
ptoms prolonged fever, hepatosplenomegaly, and cytopenias. The most prominent histopathological feature of HLH is an
accumulation of activated T lymphocytes and macrophages predominantly in lymphoid tissues. Although it can occur in
all age groups, neonatal-onset HLH is very rare. We report on a case of HLH presenting with anemia and respiratory dis-
tress at birth. Several weeks prior to diagnosis the symptoms were attributed to a systemic infection. The child developed
typical clinical and laboratory findings, and was diagnosed with HLH according to HLH-2004 guidelines. Chemo-
-immunotherapy was initiated, but after a temporary control of the disease the patient succumbed to rapidly progressive
HLH. Post-mortem, extensive hemophagocytosis was found in multiple organs. No specific genetic defect was identified.
HLH is potentially fatal childhood disease. It is important for pediatricians to be able to early identify this disorder and
commence the therapy before overwhelming disease activity develops.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare
disorder characterized by widespread accumulation of
lymphocytes and mature macrophages, sometimes with
hemophagocytosis, primarily involving the spleen, lymph
nodes, bone marrow, liver and cerebrospinal fluid1. The
hallmark of HLH is an uncontrolled hyperinflammation,
caused by unremitting activation of CD8+ T cells and
macrophages, and excessive levels of cytokines2. The
symptoms and signs may vary widely, but the most typi-
cal findings are prolonged fever, hepatosplenomegaly and
cytopenias3.
HLH comprises two different conditions: primary or
genetic HLH, and secondary or acquired hemophagocytic
syndrome (secondary HLH, sHLH). These two forms
may be difficult to distinguish from one another1.
Familial hemophagocytic lymphohistiocytosis (FHL)
is a subgroup of genetic HLH inherited in an autosomal
recessive manner. The incidence has been estimated to
1.2/1.000.000 children per year, i.e. 1:50.000 live-born4.
Most children develop the disease very early in life with
around 70% less than 1 year of age at onset. FHL may
also present at birth or even at prenatal investigations.
Several genetic defects underlying FHL have been dis-
covered recently and have elucidated the pathophysio-
logy of the disease. Without treatment, FHL is invariably
fatal, with a median survival of 2 months after diagno-
sis4,5.
We present a two-month-old male infant with very
early neonatal presentation. The patient was misdiag-
nosed with sepsis and accompanying anemia for several
weeks prior to diagnosis of HLH.
Case Report
A 4-day-old male neonate was transferred to Univer-
sity Children’s Hospital Rijeka from the Division of Neo-
natology, Department of Obstetrics and Gynecology, for
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further observation. He was born at 34 weeks’ gestation,
with a birth weight of 1.800 g, length 45 cm, and Apgar
scores of 5 and 6 at 1 and 5 minutes respectively. During
the first hours of life the child developed respiratory dis-
tress accompanied by anemia (hemoglobin 80 g/L) re-
quiring transfusion therapy. On the second day of life the
patient became icteric and hypotonic. He was the first
child of non-consanguineous healthy parents. Maternal
serum screening tests for toxoplasmosis, syphilis, ru-
bella, hepatitis B, Epstein-Barr virus (EBV), cytomega-
lovirus (CMV), herpes simplex virus (HSV), and human
immunodeficiency virus (HIV) were negative. Prenatal
ultrasound examinations had shown normal fetal growth
and development. The family history was notable for two
father’s siblings having died in infancy for unknown rea-
sons.
On admission to our hospital the patient was hypo-
tonic, pale and icteric. Antibiotic treatment (ampicillin
and gentamycin) was given for presumed systemic infec-
tion. During the third week of life his general condition
worsened, with pallor, fever (>38.5 °C) and hepatosple-
nomegaly. The laboratory findings were as follows: RBC
3.49109/L, hemoglobin 75 g/L, WBC 6.7109/L (neutro-
phils 42%), platelets 289109/L, reticulocytes 2.5%, LDH
437 IU/L, ferritin 662 mg/L, total protein 4.2 g/dL with
albumin 2.7 g/dL, and C-reactive protein 24.3 mg/L.
Blood cultures were negative. RBC transfusion, broad
spectrum antibiotics, acyclovir and intravenous immu-
noglobulins were given, and his general condition tempo-
rarily improved. During the following weeks, the patient
suffered from multiple episodes of fever. Repeated bacte-
rial blood cultures were negative. Serologic tests for HSV,
CMV, EBV, parvovirus B19, enteroviruses, adenoviruses,
and hepatitis B and C viruses were negative. Other find-
ings included persistent hyperferritinemia (max. 1820
mg/L) and hypofibrinogenemia (min. 0.9 g/L). In the
eighth week of life the child’s condition deteriorated with
high fever, irritability, bulging fontanel, hypertonus, al-
tered consciousness, massive hepatosplenomegaly with
abdominal distension, and multiple firm subcutaneous
nodules. He had severe anemia and mild thrombocyto-
penia. Examination of a spinal fluid revealed mononuc-
lear pleocytosis and elevated protein content. Magnetic
resonance imaging of the brain was normal. Abdominal
ultrasound and computed tomography showed enlarged
spleen and enlarged hyperdense liver. At this point the
child was referred to the hematologist for a further eval-
uation. Because of the high suspicion of HLH, bone mar-
row aspiration was performed. Myelopoiesis shifted to-
wards immaturity and limited erythropoiesis was pre-
sent, without evidence of hemophagocytosis. A biopsy of
a subcutaneous nodule from the lower abdomen demon-
strated lobular panniculitis and numerous histiocytes
with cytophagocytosis (Figure 1). Triglyceride levels
were normal. Flow cytometric immunophenotyping of
peripheral blood revealed significantly lower percentage
of CD19+ B-lymphocytes (25%). Relative percentage of
helper T lymphocytes (CD3+CD4+) was higher (67%),
while percentage of cytotoxic T lymphocytes (CD3+
CD8+) was lower (10%). The CD4/CD8 ratio was 6.65
(normal range 0.9–3.4). The percentage of the peripheral
blood NK-cells (CD56+) was normal (13%). Serum levels
of immunoglobulins were decreased. Testing for soluble
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Fig. 1. Cytophagic histiocytic panniculitis: (a) an intense inflammatory cell infiltration present at the junction between the dermis
and subcutaneous fat; (b) consisted predominantly of histiocytes with abundant eosinophilic cytoplasm and irregular vesicular
nuclei; (c) with some cells which demonstrated erithrophagocytosis; (d) and positive for CD68 immunostaining.
interleukin-2 receptor, perforin expression, and natural
killer (NK)-cell activity was not available.
Altogether, clinical and laboratory parameters ful-
filled the criteria for the diagnosis of HLH, and the treat-
ment according HLH-2004 protocol was initiated (dexa-
methasone, etoposide, cyclosporine A). The child’s gene-
ral condition, neurological disturbances and organome-
galy much improved, with a fever and skin nodules
resolving within 2 days and 7 days respectively. His labo-
ratory parameters also improved significantly. The pa-
tient had no available HLA-identical related donor, and it
was decided to carry out the international search for an
unrelated donor for hematopoietic stem cell transplanta-
tion.
Two weeks after the start of the treatment the pa-
tient’s condition rapidly deteriorated with high fever,
generalized edema, enlarged spleen, severe anemia,
thrombocytopenia, and hyperferritinemia (5100 ng/mL).
The bone marrow was hypocellular, with normal hemato-
poietic elements being replaced by macrophages that ex-
hibited erythrophagocytosis (Figure 2).
The clinical condition of a child further deteriorated
with circulatory and respiratory insufficiency requiring
mechanical ventilation. Chest X-ray showed bilateral in-
terstitial pneumonia and cardiomegaly. Echocardiogra-
phy confirmed marked enlargement of left ventricle with
significantly decreased contractility. Multiple organ dys-
function syndrome (MODS) developed, and the patient
died of cardiorespiratory failure and disseminated intra-
vascular coagulation at the age of 3.5 months, four weeks
after the initiation of the treatment.
At autopsy, extensive lymphohystiocytic hemophago-
cytosis was identified in the bone marrow, lungs, liver
and spleen. Post-mortem genetic tests for FHL including
PRF1 (FHL2), UNC13D (FHL3), and STX11 (FHL4)
were negative. No mutations were found in both parents.
Discussion
HLH encompasses a heterogeneous class of rare but
potentially fatal disorders characterized by multisystem
inflammation, which results from prolonged and intense
activation of antigen- presenting cells (macrophages, his-
tiocytes) and CD8+T-cells, and excessive proliferation
and ectopic migration of T-cells2. It comprises two differ-
ent conditions: primary or genetic, and secondary or ac-
quired form. Genetic HLH is inherited in an autosomal
recessive or X-linked fashion and can be divided into two
subgroups: familial hemophagocytic lymphohystiocytosis
(FHL) in which the clinical syndrome of HLH is the only
manifestation, and HLH associated with inherited im-
mune deficiencies Chediak-Higashi syndrome, Griscelli
syndrome, and X-linked lymphoproliferative syndrome
which have distinctive clinical features besides the spo-
radic development of HLH5,6. Acquired (secondary) forms
of HLH may develop as a result due to strong immuno-
logical activation of the immune system, which may be
caused by a severe infection and malignancy. Leading
triggering agents in infection-associated hemophagocytic
syndrome (IAHS) are viruses of the herpes group, espe-
cially EBV and CMV. Acquired HLH in association with
malignant disease (malignancy-associated hemophago-
cytic syndrome, MAHS), especially lymphomas, can de-
velop before or during treatment. Macrophage-activation
syndrome (MAS) is a special form of HLH which occurs
in children and adults with autoimmune diseases5.
Despite attempts to differentiate primary from sec-
ondary HLH, the clinical presentation is highly overlap-
ping2. Prolonged fever (>7 days) and hepatosplenome-
galy are cardinal findings. Neurological symptoms may
dominate the initial clinical course, including irritability,
seizures, hypo- and hypertonia, cranial nerve palsies, and
altered consciousness. Lymphadenopathy, skin rash,
jaundice, edema, and diarrhea are less frequent. In the
early days to months of the disease, symptoms may im-
prove spontaneously, followed by exacerbations2. Charac-
teristic laboratory findings are cytopenias, especially
anemia and thrombocytopenia, coagulopathy with hypo-
fibrinogenemia, and hypertriglyceridemia. Liver dysfun-
ction, hypoalbuminemia, elevated lactate dehidrogenase,
and hyponatremia are often present1,2. Two highly diag-
nostic parameters are an increased plasma concentration
of the alpha chain of the soluble interleukin-2 receptor
(sCD25), and impaired NK cell activity. In patients with
FHL, NK cell number is normal, but the activity is per-
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Fig. 2. Bone marrow aspirate showing: (a) marked hypocellularity and (b) erithrophagocytosis.
sistently decreased or absent. Patients with acquired
HLH may have low NK cell number; NK cell function is
decreased with active disease, but usually reverts to nor-
mal after treatment5. A lumbar puncture is also recom-
mended as part of a diagnostic workup, and more than
half of patients will have a moderate pleocytosis and/or
increased protein content, even in the absence of neuro-
logical symptoms. The caution with lumbar puncture
must be taken with regard to a possibly increased intra-
cranial pressure2. All patients should have a bone mar-
row aspiration. However, frank hemophagocytosis may
not be observed early in the course of the disease, and se-
rial marrow aspirates may be helpful7,8.
Genetic studies showed that familial form of HLH
may result from mutations in different proteins involved
in granule exocytosis and perforin-dependent induction
of target cell apoptosis, mediated by NK-cells and cyto-
toxic T lymphocytes. Depending on the geographical and
ethnic origin, 15 to 50% of patients with FHL (also re-
ferred to as FHL2) have mutations in perforin gene
PRF1 at locus 10q24 that lead to impaired perforin pro-
duction. Perforin is a soluble cytolytic protein; it is able,
in the presence of calcium, to perforate into the mem-
brane of a target cell, where it polymerizes to form a cell
death-inducing pore. UNC13D mutations, at locus 17q25,
account for 15 to 20% of FHL (also referred to as FHL3).
Encoding protein Munc13-4 is essential for priming of se-
cretory vesicles and the subsequent release of cytolytic
enzymes. Recently, a third gene defect responsible for
FHL4 has been identified in Turkish families on chromo-
some 6q24 with mutations in STX11. The encoded pro-
tein, t-SNARE sintaxin 11, facilitates fusion in
intracellular membrane trafficking events2,5.
The revised diagnostic criteria for HLH, based on the
recommendations of the Histiocyte Society, are summa-
rized in Table 1. In the absence of a family history or spe-
cific molecular diagnosis, an assemblage of at least five of
the eight diagnostic criteria are needed for a diagnosis of
HLH and initiation of therapy1.
HLH is a challenging condition not only to diagnose
but as well as to treat. The immediate aim of the treat-
ment is to suppress life-threatening hyperinflammation,
caused by excessive levels of cytokines5. Another aim is
to kill pathogen-infected antigen-presenting cells, and
thus to remove the stimulus for the ongoing activation of
T-cells. The need to treat coexisting infections as poten-
tial triggers of HLH is obvious, but usually not sufficient
to control hyperinflammation3.
The overall prognosis for patients with HLH has im-
proved dramatically during the last decades as has the bi-
ological understanding of the disease. Current interna-
tional HLH 2004 protocol is designed for all patients
with newly diagnosed HLH, with or without evidence of
familial or genetic disease, and regardless of suspected or
documented infection1. The protocol represents systemic
chemo-immunotherapy including dexamethasone, cyclo-
sporine A, etoposide upfront, and, in selected patients,
intrathecal therapy with methotrexate. Corticosteroids
show cytotoxic effect and inhibit expression on cytokines.
In pediatric protocols dexamethasone is preferred than
prednisolone since it crosses the blood brain barrier
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TABLE 1
REVISED DIAGNOSTIC GUIDELINES FOR HEMOPHAGOCYTIC LYMPHOHYSTIOCYTOSIS
The diagnosis HLH can be established if one of either 1 or 2 below is fulfilled
(1) A molecular diagnosis consistent with HLH
(2) Diagnostic criteria for HLH fulfilled (five out of the eight criteria below)
(A) Initial diagnostic criteria (to be evaluated in all patients with HLH)
Fever
Splenomegaly
Cytopenias (affecting  2 of 3 lineages in the peripheral blood):
Hemoglobin <90 g/L (in infants <4 weeks: hemoglobin <100 g/L)
Platelets <100  109/L
Neutrophils <1.0  109/L
Hypertriglyceridemia and/or hypofibrinogenemia:
Fasting triglycerides  3.0 mmol/L (i.e.  265 mg/dL)
Fibrinogen  1.5 g/L
Hemophagocytosis in bone marrow or spleen or lymph nodes
No evidence of malignancy
(B) New diagnostic criteria
Low or absent NK-cell activity (according to local laboratory reference)
Ferritin  500 mg/L
Soluble CD25 (i.e. soluble IL-2 receptor)  2.400 U/mL
better. Cyclosporine A prevents T-lymphocyte activation.
Etoposide is an antineoplastic agent highly effective in
monocytic and histiocytic disorders. Intrathecal metho-
trexate is used only in patients with persistently abnor-
mal cerebrospinal fluid or progressive neurological sym-
ptoms3. The overall 3-year disease-free survival is 55%2.
In genetic HLH the ultimate aim must be hemato-
poietic stem cell transplantation (HSCT) to replace con-
genitally defective immune system with normal func-
tioning immune effector cells of healthy donors. Whereas
FHL was uniformly fatal without HSCT, with this proto-
col the overall survival rate is 58 to 64%9.
Although HLH can occur in all age groups, neonatal
onset within 4 weeks after birth is rare, accounting for
4% of all HLH cases10. Most patients have been published
as case presentations or included in childhood HLH stud-
ies, and there are very few reported series11,12. The fre-
quency of primary and secondary HLH neonatal cases
has not been well defined, and is sometimes indistin-
guishable from one another clinically and histological-
ly10. The diagnosis is frequently delayed, made on au-
topsy or missed completely. The course of neonatal HLH
is quite devastating with high mortality13. Chemo-immu-
notherapy results in the control of the disease in some
cases; however, remission is rarely sustained. The only
reported survivors were those who received conventional
therapy followed by HSCT10,12.
Our patient presented with severe anemia and respi-
ratory problems already at birth. During the neonatal
period he developed typical findings for HLH, but epi-
sodes of fever were misinterpreted as systemic infection,
although repeated microbiological examinations (bacte-
rial cultures and serologic tests) were negative. All HLH
neonatal reports emphasize the difficulties in establish-
ing the diagnosis, as HLH may mimic a number of other
diseases most frequent being congenital infection, sepsis,
inherited metabolic disorders or hemochromatosis. Mis-
leading in our case might be due to the fact that the pa-
tient improved several times in the course of the disease.
His transient improvements could be explained by the
natural course of the disease in the early phase, unspe-
cific therapy such as transfusions, or at least in part by
immunomodulation through immunoglobulins that were
given repeatedly because of a suspicion for severe infec-
tion. Immunoglobulins down-regulate proinflammatory
cytokines, block Fc receptors on macrophages, suppress
inducer T and B-cells, and augment suppressor T-cells4.
They have been mainly used in adults with HLH14.
Although molecular analysis did not reveal any known
genetic defect, very early presentation, serious clinical
course, the lack of infectious or immunological trigger-
ing, and a family history with reasonable suspicion of sib-
lings that died in early infancy, suggest that the pre-
sented case more likely suffered familial HLH. As speci-
fic genetic defects account for less than one half of FHL,
we can only speculate that reported FHL case is caused
by mutations in as yet unidentified genes.
This patient is noteworthy for the presentation in the
first days of life. Previous reports from the literature
have shown that patients with FHL were usually born
healthy but became ill in the first 2 to 6 months of life10.
In the present case HLH masqueraded as a systemic in-
fection in the following weeks, and too little attention
was paid to the severity of other symptoms. The onset of
central nervous system involvement heralded progres-
sion of the disease, but was overlooked.
We suggest that HLH should be considered in the dif-
ferential diagnosis of multisystem organ involvement in
newborns and particularly in preterm neonates, espe-
cially when no infectious or metabolic cause can be
found. Ferritin, fibrinogen and triglycerides measure-
ments should be routinely determined in these patients.
In the presence of cytopenias and hyperferritinemia, re-
ferral to the experienced hematologist is highly recom-
mended. The absence of hemophagocytosis in bone mar-
row should not be a reason to rule out the diagnosis of
HLH, as finding in up to two thirds of initial bone mar-
row aspirates may be nondiagnostic. If hemophagocytic
activity is not proven in bone marrow, material may be
obtained from other tissues, or serial marrow aspirates
over time may be required to document hemophagocy-
tosis.
Early establishment of the diagnosis of HLH has very
important implications for timely commencement of the
treatment, before overwhelming disease activity makes
irreversible damage and a response to treatment less
likely. Because neonatal HLH can be rapidly fatal with-
out specific intervention, it is recommended to start a
treatment when a high clinical suspicion exists and re-
sults of diagnostic studies are still pending2. HSCT should
be performed as early as possible, when an acceptable do-
nor is available. Genetic counseling and family planning
is of utmost importance. Subsequent pregnancies should
be closely monitored and offspring referred for genetic
testing.
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NEONATALNA HEMOFAGOCITNA HISTIOCITOZA – PRIKAZ SLU^AJA
S A @ E T A K
Hemofagocitna limfohistiocitoza (HLH) je ozbiljno stanje prekomjerne upalne reakcije karakterizirano produljenom
vru}icom, hepatosplenomegalijom i citopenijom. Najzna~ajnija patohistolo{ka zna~ajka HLH je akumulacija aktivira-
nih T limfocita i makrofaga prete`no u limfoidnim organima. Iako se mo`e javiti u svim dobnim grupama, neonatalni
po~etak bolesti je vrlo rijedak. U radu je prikazan slu~aj neonatalne HLH s anemijom i respiratornim te{ko}ama na
ro|enju. Nekoliko tjedana prije postavljene dijagnoze simptomi su tuma~eni sistemskom infekcijom. Dijagnoza HLH je
postavljena nakon razvoja tipi~nih klini~kih i laboratorijskih znakova prema HLH-2004 smjernicama. Kemoimuno-
terapijom je postignuta privremena kontrola bolesti, iza koje je uslijedio rapidni progresivni tijek. Postmortalno je na-
|ena opse`na hemofagocitoza u brojnim organima. Nije utvr|en specifi~ni genski defekt. HLH je potencijalno smrto-
nosna bolest, ~ije rano prepoznavanje i zapo~injanje terapije je od presudne va`nosti.
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